Adaptive Biotechnologies Evaluates Strategic Alternatives for Immune Medicine Business

Dow Jones06-16

By Kelly Cloonan

Adaptive Biotechnologies is evaluating strategic alternatives for its immune medicine unit as it plans to separate the business from its minimal residual disease arm.

The company said Monday it is looking at alternatives for its immune medicine business to support its growth and capital needs, and expects to decide on a path to separation by the end of the year.

Adaptive established its immune medicine and minimal residual disease businesses as separate operating segments in 2024. In the time since, immune medicine has increasingly demonstrated its potential to generate novel biological insights, identify therapeutic targets and accelerate the development of precision medicines, and Adaptive now sees it benefiting outside of a diagnostic commercial model.

"As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive," Chief Executive Chad Robins said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 15, 2026 16:50 ET (20:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643869017?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 04:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643869017","market":"nz","top_or_hot":-1,"title":"Adaptive Biotechnologies Evaluates Strategic Alternatives for Immune Medicine Business","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> is evaluating strategic alternatives for its immune medicine unit as it plans to separate the business from its minimal residual disease arm. \n</p>\n<p>\n  The company said Monday it is looking at alternatives for its immune medicine business to support its growth and capital needs, and expects to decide on a path to separation by the end of the year. \n</p>\n<p>\n  Adaptive established its immune medicine and minimal residual disease businesses as separate operating segments in 2024. In the time since, immune medicine has increasingly demonstrated its potential to generate novel biological insights, identify therapeutic targets and accelerate the development of precision medicines, and Adaptive now sees it benefiting outside of a diagnostic commercial model. \n</p>\n<p>\n  \"As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive,\" Chief Executive Chad Robins said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 15, 2026 16:50 ET (20:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies Evaluates Strategic Alternatives for Immune Medicine Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies Evaluates Strategic Alternatives for Immune Medicine Business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-16 04:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> is evaluating strategic alternatives for its immune medicine unit as it plans to separate the business from its minimal residual disease arm. \n</p>\n<p>\n  The company said Monday it is looking at alternatives for its immune medicine business to support its growth and capital needs, and expects to decide on a path to separation by the end of the year. \n</p>\n<p>\n  Adaptive established its immune medicine and minimal residual disease businesses as separate operating segments in 2024. In the time since, immune medicine has increasingly demonstrated its potential to generate novel biological insights, identify therapeutic targets and accelerate the development of precision medicines, and Adaptive now sees it benefiting outside of a diagnostic commercial model. \n</p>\n<p>\n  \"As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive,\" Chief Executive Chad Robins said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 15, 2026 16:50 ET (20:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2643869017","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643869017","pubTimestamp":1781556600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Adaptive Biotechnologies is evaluating strategic alternatives for its immune medicine unit as it plans to separate the business from its minimal residual disease arm.The company said Monday it is looking at alternatives for its immune medicine business to support its growth and capital needs, and expects to decide on a path to separation by the end of the year.Adaptive established its immune medicine and minimal residual disease businesses as separate operating segments in 2024. In the time since, immune medicine has increasingly demonstrated its potential to generate novel biological insights, identify therapeutic targets and accelerate the development of precision medicines, and Adaptive now sees it benefiting outside of a diagnostic commercial model.\"As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive,\" Chief Executive Chad Robins said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp","BK4121":"生命科学工具和服务"},"translate_title":"Adaptive Biotechnologies评估免疫医学业务的战略选择","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\nAdaptive Biotechnologies is evaluating strategic alternatives for its immune medicine unit as it plans to separate the business from its minimal residual disease arm. \n\n\n  The company said Monday it is looking at alternatives for its immune medicine business to support its growth and capital needs, and expects to decide on a path to separation by the end of the year. \n\n\n  Adaptive established its immune medicine and minimal residual disease businesses as separate operating segments in 2024. In the time since, immune medicine has increasingly demonstrated its potential to generate novel biological insights, identify therapeutic targets and accelerate the development of precision medicines, and Adaptive now sees it benefiting outside of a diagnostic commercial model. \n\n\n  \"As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive,\" Chief Executive Chad Robins said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 16:50 ET (20:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643869017","isCrawlerRequest":true}